Clinical

The rate of invasive pneumococcal disease in children plummeted by 72% from 2002 to 2021; health care spending in the United States rose 4.1% in 2022 to $4.5 trillion; roughly two-thirds of Americans who have a mental health condition were unable to access treatment in 2021 despite having health insurance.

While past studies have shown the connection between poor sleep and job performance, this research dives deeper into the experience of this specific population.

Key opinion leaders underscore the importance of a multidisciplinary approach that can break down barriers and advance CSCC and BCC therapy.

The US Preventive Services Task Force (USPSTF) recommended that children with obesity receive intensive counseling at age 6 to promote healthy diet and exercise habits; a new survey found that the majority of American patients are wary of their doctors using artificial intelligence (AI); a class-action lawsuit was filed Tuesday against health insurer Humana for using an AI algorithm that systemically denies seniors rehabilitation care recommended by their doctors.

Experts explore the optimal sequencing of immunotherapy relative to radiation therapy in CSCC and BCC care.

From 2013 to 2022, the all-cause mortality rate among patients with HIV in China declined from 5.4% to 2.7%.

Patients with metastatic colorectal cancer (CRC) who experience colon perforation may have similar survival times to those without perforation.

Elaine Siegfried, MD, of Saint Louis University School of Medicine discusses the use of biologics to treat atopic dermatitis (AD) and how they differ from other treatments.

BCMA-directed CAR T-cell therapy anitocabtagene autoleucel demonstrated a 76% complete remission rate and 89% negative minimal residual disease in patients with relapsed/refractory multiple myeloma.

Patients with age-related macular degeneration (AMD) who were not responsive to anti–vascular endothelial growth factor agents were able to increase their fluid-free intervals with faricimab.

In AUGMENT-101, patients with R/R KMT2Ar acute leukemia had high overall response rates; despite being heavily pretreated, 40% were able to proceed to transplant and the KMT2Ar cohort was stopped early.

Ciprofloxacin, ceftriaxone, and piperacillin/tazobactam showed the greatest associations with adverse drug reaction case reports related to C difficile.

A late-breaking abstract presented at the American Society of Hematology Annual Meeting and Exposition supports the addition of subcutaneous daratumumab to standard-of-care bortezomib, lenalidomide, and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation.

Adding metformin to the insulin regimen for pregnant patients with preexisting type 2 diabetes (T2D) or gestational diabetes diagnosed early in pregnancy did not reduce the risk of neonatal adverse outcomes.

Panelists provide final considerations surrounding biosimilar usage and considerations for optimal patient care.

Key topics for patient-provider conversations within the biosimilar landscape are highlighted by expert panelists.

Predicting clinical outcomes in patients with colorectal cancer (CRC) could be done using the novel comprehensive blood indicator PSI.

Experts address the need for lower costs of treatment, as well as ways payers can support patients with the use of biologics.

A medication monitoring program using medication bottles waws found to be effective in patients with sickle cell disease (SCD), though the usage will need additional support.

Among adults with type 2 diabetes who started noninsulin second-line therapy, most modified treatment within 1 year. Discontinuation was by far the most common modification.

Patients with B-cell malignancies who were intolerant to treatment with acalabrutinib experienced clinically meaningful benefits when treated with zanubrutinib, suggesting zanubrutinib may be a viable treatment option for this population.

Kevin Sheth, MD, discusses the role of computed tomography perfusion amid stroke diagnosis.

A trial comparing baricitinib against placebo in people with new-onset type 1 diabetes suggests use could contribute to the preservation of β-cell function.

A panel of medical experts discuss obstacles hindering the full potential of bispecifics.

Experts explore optimal conditions for effective bispecific therapy in an insightful panel discussion.